Pharmaceutical Stocks To Keep An Eye On - August 6th

Key Points

• Eli Lilly and Company is a key stock in the pharmaceutical sector, currently trading at $742.77 with a market capitalization of $703.95 billion.
• Vertex Pharmaceuticals focuses on cystic fibrosis therapies and saw its stock rise to $387.15, supported by robust trading volume exceeding its average.
• Novo Nordisk A/S is engaged in diabetes and obesity care, with its stock priced at $45.40, reflecting higher trading volume compared to its typical activity.

Eli Lilly and Company, Vertex Pharmaceuticals, and Novo Nordisk A/S are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs, vaccines and other therapeutic products. Owning these stocks gives investors exposure to the biotechnology and drug-development sector’s potential growth, profitability and inherent risks. Their performance often hinges on factors such as clinical trial outcomes, regulatory approvals and patent lifecycles. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

LLY stock traded down $23.19 during midday trading on Wednesday, reaching $742.77. The company had a trading volume of 2,417,133 shares, compared to its average volume of 3,792,473. The company has a market capitalization of $703.95 billion, a price-to-earnings ratio of 60.47, a price-to-earnings-growth ratio of 1.09 and a beta of 0.44. The stock has a 50 day moving average price of $777.42 and a 200-day moving average price of $800.57. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Read Our Latest Research Report on LLY

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX stock traded up $12.17 during midday trading on Wednesday, reaching $387.15. The company had a trading volume of 3,319,689 shares, compared to its average volume of 1,599,789. The company has a market capitalization of $99.42 billion, a price-to-earnings ratio of 27.56 and a beta of 0.44. The stock has a 50 day moving average price of $454.92 and a 200-day moving average price of $466.81. Vertex Pharmaceuticals has a 1-year low of $372.35 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Read Our Latest Research Report on VRTX

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

NVO stock traded down $1.82 during midday trading on Wednesday, reaching $45.40. The company had a trading volume of 26,804,630 shares, compared to its average volume of 10,969,386. The company has a market capitalization of $202.71 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 1.48 and a beta of 0.63. The stock has a 50 day moving average price of $68.43 and a 200-day moving average price of $72.20. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Read Our Latest Research Report on NVO

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.